OnCo

A growth receptor amplified in squamous lung cancer and fused in a rare blood cancer. Pemigatinib is approved for the FGFR1-rearranged myeloid and lymphoid neoplasm, and pan-FGFR drugs block FGFR1 too, which is why they raise blood phosphate. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Receptor tyrosine kinase; gene amplification in squamous cancers and fusions in the 8p11 myeloproliferative syndrome; renal FGFR1 mediates the hyperphosphataemia of pan-FGFR inhibitors.

Where it is found
  • Myeloid or lymphoid neoplasm with FGFR1 rearrangement
  • Squamous non-small-cell lung cancer (amplification)
  • Hormone receptor-positive breast cancer (amplification)
Class: kinase · Gene: FGFR1 · Facts checked 2026-09-04 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

How common it is in each cancer

Full matrix →
CancerPrevalenceSource
Non-small-cell lung cancer
about 20%
doi.org

Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"FGFR1" OR ABSTRACT:"FGFR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGFR1, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/fgfr1.json. Licence CC BY-NC 4.0.